ravulizumab

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

ravulizumab is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 27, 2027 (day precision, medium confidence), tied to trial NCT07596784. The asset is in Phase 3 and currently not yet recruiting, studied in Generalized Myasthenia Gravis. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-08-27

As disclosedAug 27, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT07596784

PhasePHASE3

StatusNOT_YET_RECRUITING

Lead sponsorAlexion Pharmaceuticals, Inc.

Listed asAZN

Condition(s)Generalized Myasthenia Gravis; gMG

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AZN catalysts